Company intelligence / Profile preview

InnerThera

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

InnerThera is a preclinical-stage biotechnology company focused on developing next-generation small molecule therapies for neurological disorders. The company's primary focus is on the discovery and development of selective potassium channel openers, specifically targeting the KCNQ2/3 channels to treat conditions such as epilepsy and chronic pain. By leveraging deep expertise in ion channel pharmacology, InnerThera aims to create precision medicines that offer improved efficacy and safety profiles compared to existing anti-seizure medications. The company is currently advancing its lead programs through lead optimization and IND-enabling studies.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on InnerThera.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on InnerThera.

Explore the full profile